CELLSEARCH Circulating Tumor Cell Test
The CELLSEARCH CTC Test is a simple, actionable blood test that helps oncologists assess the prognosis of patients with metastatic breast, prostate, or colorectal cancer. It is the first and only clinically validated, FDA-cleared blood test for enumerating circulating tumor cells (CTCs). CTCs are cancer cells that detach from a primary tumor and travel through the bloodstream or lymphatic system to other parts of the body. CTCs are a strong, independent predictor of overall and progression-free survival in metastatic breast, prostate and colorectal cancer. The CELLSEARCH system enables the enrichment and enumeration of rare cell types — from circulating tumor cells (CTCs) to circulating endothelial cells from blood and is based on ferrofluid technology which allows the immune-magnetic capture of rare cells in the whole blood. CELLSEARCH Circulating Tumor Cell Test can help you make more informed patient care decisions. This simple blood test gives you earlier assessment of prognosis than PSA in patients with metastatic prostate cancer, detection of changes in prognosis at any time, and assurance that you have a complete picture of the status of your patient when used with other clinical indicators. Order the test at any time during the course of the disease to assess prognosis and to inform patient care. For further information on intended use, warnings, and limitations, please refer to the CELLSEARCH CTC Test Instructions for Use, or visit www.cellsearchctc.com. Clinical indicators include all information derived from diagnostic tests (eg, imaging, laboratory tests), physical examination, and complete medical history. Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management. These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer.
...
More Info Less Info